OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use

<p><b>Declarations</b><br></p><p><b><br></b></p> <p><b>Funding</b> The preparation of the Adis Drug Review was not supported by any external funding.<br></p> <p><b>Authorship and Conflict of interest</b> James Frampton is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.<br></p> <p><b>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</b> not applicable<br></p> <p><br></p><p>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a></p> <p><br></p><p><b>Abstract</b></p> <p>OnabotulinumtoxinA (Botox^®; a formulation of botulinum toxin type A (BoNT/A)] is indicated for the prevention of headaches in adults with chronic migraine (CM) in numerous countries, including those of Europe. In clinical trials, intramuscular administration of BoNT/A (155–195 units at 12-week intervals) to patients with CM was generally well tolerated and associated with sustained and clinically meaningful improvements in multiple assessments of headache symptoms, headache-related impact and/or disability and migraine-specific health-related quality of life over a period of 1 year (in the pivotal PREEMPT 1 and 2 studies) and 2 years (in the phase IV COMPEL study). The efficacy and safety of BoNT/A therapy have been confirmed in a number of large, prospective, real-world studies conducted in Europe, including the 2-year REPOSE study. Intramuscular BoNT/A has also demonstrated greater clinical utility than the oral prophylactic medication topiramate in a clinical practice setting (FORWARD study).</p><p><br></p><p><b>Video Abstract, Script and Slides</b></p><p><b><br></b></p><p>The video abstract, script and slide deck of images from the video, which have been peer reviewed and were uploaded to Figshare after the OnabotulinumtoxinA in Chronic Migraine Adis Drug Q&A was published, are sponsored by AbbVie.</p><p><br></p><p>The script and slide deck can be found <a href="https://adisjournals.figshare.com/articles/online_resource/_/14410499">here</a>.</p><p><b><br></b></p><p><b><br></b></p> <p> </p> <p>© Springer Nature Switzerland AG 2021</p><br><br>